Skip to content
  • Submit

  • Category

  • Sort by

  • Per page

Found 9849 publications. Showing page 143 of 394:

Publication  
Year  
Category

Extensive release of methane from Arctic seabed west of Svalbard during summer 2014 does not influence the atmosphere.

Myhre, C.L.; Ferré, B.; Platt, S.M.; Silyakova, A.; Hermansen, O.; Allen, G.; Pisso, I.; Schmidbauer, N.; Stohl, A.; Pitt, J.; Jansson, P.; Greinert, J.; Percival, C.; Fjaeraa, A.M.; O'Shea, S.J.; Gallagher, M.; Le Breton, M.; Bower, K.N.; Bauguitte, S.J.B.; Dalsøren, S.; Vadakkepuliyambatta, S.; Fisher, R.E.; Nisbet, E.G.; Lowry, D.; Myhre, G.; Pyle, J.A.; Cain, M.; Mienert, J.

2016

Extracellular Vesicles as Next-Generation Diagnostics and Advanced Therapy Medicinal Products

Stawarska, Agnieszka; Bamburowicz-Klimkows, Magdalena; Rundén-Pran, Elise; Dusinska, Maria; Cimpan, Mihaela Roxana; Rios Mondragon, Ivan; Grudzinski, Ireneusz P.

Extracellular vesicles (EVs) hold great promise for clinical application as new diagnostic and therapeutic modalities. This paper describes major GMP-based upstream and downstream manufacturing processes for EV large-scale production, also focusing on post-processing technologies such as surface bioengineering and uploading studies to yield novel EV-based diagnostics and advanced therapy medicinal products. This paper also focuses on the quality, safety, and efficacy issues of the bioengineered EV drug candidates before first-in-human studies. Because clinical trials involving extracellular vesicles are on the global rise, this paper encompasses different clinical studies registered on clinical-trial register platforms, with varying levels of advancement, highlighting the growing interest in EV-related clinical programs. Navigating the regulatory affairs of EVs poses real challenges, and obtaining marketing authorization for EV-based medicines remains complex due to the lack of specific regulatory guidelines for such novel products. This paper discusses the state-of-the-art regulatory knowledge to date on EV-based diagnostics and medicinal products, highlighting further research and global regulatory needs for the safe and reliable implementation of bioengineered EVs as diagnostic and therapeutic tools in clinical settings. Post-marketing pharmacovigilance for EV-based medicinal products is also presented, mainly addressing such topics as risk assessment and risk management.

MDPI

2024

Extraordinary halocarbon emissions initiated by the 2011 Tohoku earthquake.

Saito, T.; Fang, X.; Stohl, A.; Yokouchi, Y.; Zeng, J.; Fukuyama, Y.; Mukai, H.

2015

Extreme climate of the global troposphere and stratosphere in the 1940-42 related to El Nino.

Brönnimann, S.; Luterbacher, J.; Staehelin, J.; Svendby, T. M.; Hansen, G.; Svenøe, T.

2004

EYE-CLIMA: A Horizon Europe project using atmospheric inversions to improve national estimates of greenhouse gas emissions

Winiwarter, Wilfried; Thompson, Rona Louise; Stohl, Andreas; Peylin, Philippe; Ciais, Philippe; Boesch, Hartmuth; Aalto, Tuula; Berchet, Antoine; Kanakidou, Maria; Peters, Glen Philip; Shchepashchenko, Dmitry; Chang, Jean-Pierre; Fuß, Roland; Pisso, Ignacio; Engelen, Richard; Arneth, Almuth; Buchmann, Nina; Reimann, Stefan; Platt, Stephen Matthew; Krishnankutty, Nalini

2025

Facilitating knowledge transfer: decision support tools in environment and health.

Liu, H.-Y.; Bartonova, A.; Neofytou, P.; Yang, A.; Kobernus, M.J.; Negrenti, E.; Housiadas, C.

2012

Factors affecting bioaccumulation of cyclic volatile methyl siloxanes in a subarctic benthopelagic food web.

Krogseth, I. S.; Undeman, E.; Evenset, A.; Christensen, G. N.; Whelan, M. J.; Breivik, K.; Evenset, A.; Warner, N. A.

2017

Factors affecting bioaccumulation of cyclic volatile methyl siloxanes in a subarctic benthopelagic food web.

Krogseth, I. S.; Undeman, E.; Evenset, A.; Christensen, G. N.; Whelan, M. J.; Breivik, K.; Evenset, A.; Warner, N. A.

2017

Publication
Year
Category